![James Nagarajah on [177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study](https://storage.buzzsprout.com/2qje4mhmh5n25g8ju03wk4f4l9t4?.jpg)
James Nagarajah on [177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study
About this episode
Cheryl Reeves interviews Professor James Nagarajah about his study on [177Lu]-PSMA-617 in oligometastatic hormone sensitive prostate cancer.
Cheryl Reeves, Senior Editor at The Lancet Oncology, is joined by Professor James Nagarajah to discuss his open-label, randomised, phase 2 study [177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE). Click here to read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00762-4/fulltext Tell us what you thought about this episode Medical imaging and theranostics are revolutionising how we diagnose, treat, and understand dise...
More episodes of The Lancet Oncology in conversation with
- Fred Saad on quality of life in patients with metastatic hormone-sensitive prostate cancer
- Ali Landman on the European Congress of Radiology 2026
- Kayleigh Bhangdia on breast cancer GBD study 2023
- Dylan Graetz and Erica Kaye on qualitative research in oncology
- Jesse Plascak and Marissa Baker on cancer mortality rates by occupation among US workers
- Andre Pfob and Peter Dubsky on The Lucerne Toolbox 3
Explore listener stats, chart rankings, contacts and more on the The Lancet Oncology in conversation with podcast page.